Fluentide

A Chinese podcast · Same story, 4 levels

Personalized Melanoma Vaccine Cuts Recurrence Risk — episode cover art
2:07

莫德纳和默沙东公布个体化癌症疫苗结果

Personalized Melanoma Vaccine Cuts Recurrence Risk

About this story

Moderna and Merck report a personalized mRNA vaccine plus an existing cancer drug delayed melanoma recurrence and cut distant spread. HSK 5-6 Chinese listening practice.

This is an HSK 5-6 Chinese listening episode that runs about 2 minutes. The full Mandarin script is shown with tap-for-pinyin and a line-by-line English translation, so you can listen and read at once — comprehensible input in the sense of Stephen Krashen's i+1 theory. It teaches 12 key vocabulary words such as 参加、降低、获得 and walks through 3 grammar patterns, each explained in English with examples. The same news story is retold at 4 difficulty levels — use the level selector above to find the version that is challenging but still understandable for you.

Read at your level

原文

Read the complete story in Chinese. Reveal pinyin and English only when you need them.

八月十九日,莫德纳和默沙东公布了一项重要结果:个体化 mRNA 疫苗与现有癌症药一起使用,让高风险黑色素瘤患者更久没有复发。
联合治疗也降低了癌症向身体远处转移的风险。
这项最后阶段试验有一千一百三十七名患者参加。
所有患者都先做过手术;研究人员随后把他们分成两组。
一组使用现有癌症药,另一组同时使用这种药和个人疫苗。
这条新闻的核心,是每支疫苗都从患者自己的肿瘤开始制作。
团队读取肿瘤里的突变,寻找只在癌细胞中出现的目标。
然后,他们为这个患者制作一支带有这些目标信息的 mRNA 疫苗。
人体细胞读到这段信息后,会让免疫系统学习识别这些目标。
免疫系统将来遇到相同的癌细胞,就能更快发动攻击。
原来的癌症药同样帮助免疫系统工作。
它会解除癌细胞给 T 细胞设置的阻挡,让 T 细胞更容易攻击癌细胞。
这支疫苗给手术后的病人使用,属于辅助治疗。
它希望在复发前找到并清除少量留下的癌细胞。
这是个体化癌症疫苗首次在大型随机试验中达到主要目标。
不过,公开内容仍是初步结果。
两家公司还没有发布完整效果大小、长期生存数据、生活质量数据和全部副作用资料。
疫苗也还没有获得监管机构批准。
接下来,完整数据要接受医学会议和监管机构的检查。
如果结果确认,癌症药物可能从大批生产同一种药,走向为每名患者制作不同方案。
这条路的考验也很现实:测序、制造和送到医院都要赶上手术后的时间。
你觉得,个体化治疗先要解决速度,还是价格?
English transcript reference

On August 19, Moderna and Merck announced an important result: a personalized mRNA vaccine used with an existing cancer drug kept high-risk melanoma from recurring for longer.

The combined treatment also lowered the risk of distant metastasis.

The final-stage trial included 1,137 patients.

All patients had surgery first, after which researchers divided them into two groups.

One group received the existing cancer drug; the other received that drug plus a personalized vaccine.

The central point is that each vaccine begins with the patient’s own tumor.

The team reads mutations in the tumor and looks for targets found only in cancer cells.

It then makes an mRNA vaccine carrying information about those targets for that patient.

Human cells read the information and help the immune system learn to recognize those targets.

If the immune system later encounters matching cancer cells, it can attack more quickly.

The existing cancer drug also helps the immune system work.

It removes a block that cancer cells place on T cells, making it easier for T cells to attack.

The vaccine is used after surgery as an adjuvant treatment.

Its aim is to find and remove small numbers of cancer cells before recurrence.

This is the first personalized cancer vaccine to meet its main goal in a large randomized trial.

However, only preliminary results have been released.

The companies have not released the full effect size, mature overall-survival data, quality-of-life data, or complete safety information.

The vaccine has not received regulatory approval.

The complete data must next be examined at a medical meeting and by regulators.

If confirmed, cancer drugs could move from mass-producing one medicine toward making a different treatment for each patient.

The practical test is whether sequencing, manufacturing, and hospital delivery can fit the window after surgery.

Which problem should personalized treatment solve first: speed or price?

Listen again

Try it without the transcript and notice what sounds clearer.

What vocabulary does this episode teach?

词汇
cānjiāto take part in

HSK 3. 这项最后阶段试验有一千一百三十七名患者参加。

jiàngdīto reduce; to lower

HSK 3. 联合治疗也降低了癌症向身体远处转移的风险。

huòdéto obtain

HSK 3. 疫苗也还没有获得监管机构批准。

jiēshòuto receive; to undergo

HSK 3. 完整数据要接受医学会议和监管机构的检查。

jiějuéto solve

HSK 3. 个体化治疗先要解决速度,还是价格?

héxīncore

HSK 4. 这条新闻的核心,是每支疫苗都从患者自己的肿瘤开始制作。

shǔyúto belong to; to count as

HSK 4. 这支疫苗给手术后的病人使用,属于辅助治疗。

shùjùdata

HSK 4. 两家公司还没有发布完整效果大小、长期生存数据……

gètǐhuàpersonalized; individualized

个体化 mRNA 疫苗与现有癌症药一起使用。

tūbiànmutation

团队读取肿瘤里的突变,寻找只在癌细胞中出现的目标。

zhuǎnyímetastasis; to spread

联合治疗也降低了癌症向身体远处转移的风险。

fùfārecurrence

让高风险黑色素瘤患者更久没有复发。

* beyond level超纲词

What grammar patterns appear in this episode?

语法

与……一起

Together with. The result is for the vaccine used alongside an existing cancer drug, not the vaccine alone.

个体化 mRNA 疫苗与现有癌症药一起使用

还没有

Still has not. The companies have not released full data, and the vaccine is not approved yet.

两家公司还没有发布完整效果大小、长期生存数据、生活质量数据和全部副作用资料。

疫苗也还没有获得监管机构批准。

如果

If. Only if the result holds would cancer drugs move from one product for everyone to a different plan for each patient.

如果结果确认,癌症药物可能从大批生产同一种药,走向为每名患者制作不同方案。

Proper nouns

专有名词
莫德纳MòdénàModerna默沙东MòshādōngMerck (MSD)黑色素瘤hēisèsùliúmelanomaT 细胞T xìbāoT cell

Sources

来源

Free account

Keep learning from this story

Create a free account to keep saved words and your preferred level together.

  • Keep words with their story context
  • Remember your preferred level
  • Build your vocabulary over time

Keep learning